INDIA MARKET LENS
Companies▲ PositiveQuarterly Results

Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business

Mankind Pharma moved higher in a quarterly results development for Q2 FY27.

· BS Companies

The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.

Period
Q2 FY27

Mankind Pharma reported ₹4,338 crore for Q2 FY27, with movement of 37.7% and 17.3% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.

Against that, the stock is +4.5% on the day at ₹2,312.00, and has returned -7.8% over three months. It sits 12% below its 52-week high. The pharma & healthcare sector has moved -3.1% over the same period, so Mankind Pharma is running 4.7 points behind its peers.

For Mankind Pharma, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.

  • Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
  • In focus: Mankind Pharma (MANKIND), in Pharma & Healthcare.
  • Over three months: Mankind Pharma -7.8% against Pharma & Healthcare -3.1% (4.7 points behind).
Figures for the companies in this story
CompanyPriceDay1M3MFrom 52-wk highVolume vs 20-dayMarket cap
Mankind PharmaMANKIND · Pharma & Healthcare₹2,312.00+4.5%-6.6%-7.8%-11.7%1.6×—

Pharma & Healthcare

1M -8.3% · 3M -3.1%

Mankind Pharma

Prices as of 26 Oct 2026, 16:53 IST. Sector moves are the average of the stocks we track in each sector.

MANKINDPharma & Healthcare